Ion Torrent

Fluidigm Corporation is a leading biotechnology company based in South San Francisco, CA. They specialize in developing innovative technologies and instruments for life sciences research, with a focus on imaging mass cytometry, mass cytometry, and microfluidics. Their cutting-edge products and services cater to various areas of interest, including genomics, immune profiling, infectious disease analysis, and single-cell analysis. With a strong commitment to scientific excellence and customer satisfaction, Fluidigm Corporation is dedicated to advancing research and discovery in the field of biotechnology. Fluidigm Corporation offers a wide range of instruments, kits, reagents, and software solutions to support diverse research needs. Their advanced technologies, such as the CyTOF XT, Helios, and Hyperion Imaging Systems, enable high-throughput genomics, spatial biology analysis, and immune profiling. Additionally, they provide comprehensive services, including scientific consultation, training, and custom assay design. With a focus on innovation and collaboration, Fluidigm Corporation continues to be a trusted partner for researchers and scientists worldwide.Generated from the website

Achaogen, based in South San Francisco, CA, is a pharmaceutical company that specializes in the development and production of innovative treatments for complicated urinary tract infections (cUTI). Their flagship product, ZEMDRI plazomicin injection, is approved for use in the United States and is indicated for the treatment of cUTI caused by certain susceptible microorganisms. Achaogen is committed to providing healthcare professionals with effective and safe treatment options for patients with limited or no alternative therapies. With a focus on addressing the challenges of treating cUTI, Achaogen's ZEMDRI offers a mechanism of action that helps combat the infection caused by specific Enterobacterales. The company emphasizes the importance of using ZEMDRI only for proven or strongly suspected infections caused by susceptible microorganisms, and highlights the need for regular monitoring of renal function due to the risk of nephrotoxicity. Achaogen's dedication to research and development, along with their partnership with Tanner Pharma Group for international access, demonstrates their commitment to improving patient outcomes in the field of urinary tract infections.Generated from the website